Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-02-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317691186 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839599106709782528 |
|---|---|
| author | Ondrej Fiala Milos Pesek Jana Skrickova Vitezslav Kolek Frantisek Salajka Marcela Tomiskova Monika Satankova Juraj Kultan Jana Kuliskova Martin Svaton Michal Hrnciarik Karel Hejduk Renata Chloupkova Ondrej Topolcan Helena Hornychova Marketa Nova Ales Ryska Jindrich Finek |
| author_facet | Ondrej Fiala Milos Pesek Jana Skrickova Vitezslav Kolek Frantisek Salajka Marcela Tomiskova Monika Satankova Juraj Kultan Jana Kuliskova Martin Svaton Michal Hrnciarik Karel Hejduk Renata Chloupkova Ondrej Topolcan Helena Hornychova Marketa Nova Ales Ryska Jindrich Finek |
| author_sort | Ondrej Fiala |
| collection | DOAJ |
| description | Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. |
| format | Article |
| id | doaj-art-a10b69b60ee9430d88da3e92872c1cd6 |
| institution | Matheson Library |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-a10b69b60ee9430d88da3e92872c1cd62025-08-02T15:26:11ZengSAGE PublishingTumor Biology1423-03802017-02-013910.1177/1010428317691186Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapyOndrej Fiala0Milos Pesek1Jana Skrickova2Vitezslav Kolek3Frantisek Salajka4Marcela Tomiskova5Monika Satankova6Juraj Kultan7Jana Kuliskova8Martin Svaton9Michal Hrnciarik10Karel Hejduk11Renata Chloupkova12Ondrej Topolcan13Helena Hornychova14Marketa Nova15Ales Ryska16Jindrich Finek17Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech RepublicDepartment of Pneumology and Phthisiology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech RepublicDepartment of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech RepublicDepartment of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech RepublicDepartment of Pneumology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech RepublicDepartment of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech RepublicDepartment of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech RepublicDepartment of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech RepublicDepartment of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech RepublicBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech RepublicDepartment of Pneumology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech RepublicInstitute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech RepublicInstitute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech RepublicDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech RepublicThe Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech RepublicThe Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech RepublicThe Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech RepublicDepartment of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech RepublicPemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.https://doi.org/10.1177/1010428317691186 |
| spellingShingle | Ondrej Fiala Milos Pesek Jana Skrickova Vitezslav Kolek Frantisek Salajka Marcela Tomiskova Monika Satankova Juraj Kultan Jana Kuliskova Martin Svaton Michal Hrnciarik Karel Hejduk Renata Chloupkova Ondrej Topolcan Helena Hornychova Marketa Nova Ales Ryska Jindrich Finek Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy Tumor Biology |
| title | Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy |
| title_full | Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy |
| title_fullStr | Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy |
| title_full_unstemmed | Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy |
| title_short | Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy |
| title_sort | thyroid transcription factor 1 expression is associated with outcome of patients with non squamous non small cell lung cancer treated with pemetrexed based chemotherapy |
| url | https://doi.org/10.1177/1010428317691186 |
| work_keys_str_mv | AT ondrejfiala thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT milospesek thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT janaskrickova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT vitezslavkolek thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT frantiseksalajka thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT marcelatomiskova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT monikasatankova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT jurajkultan thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT janakuliskova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT martinsvaton thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT michalhrnciarik thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT karelhejduk thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT renatachloupkova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT ondrejtopolcan thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT helenahornychova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT marketanova thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT alesryska thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy AT jindrichfinek thyroidtranscriptionfactor1expressionisassociatedwithoutcomeofpatientswithnonsquamousnonsmallcelllungcancertreatedwithpemetrexedbasedchemotherapy |